Current pharmacotherapy for tic disorders
- 23 March 2020
- journal article
- review article
- Published by Taylor & Francis Ltd in Expert Opinion on Pharmacotherapy
- Vol. 21 (5), 567-580
- https://doi.org/10.1080/14656566.2020.1721465
Abstract
Introduction: Though many unanswered questions about the pathophysiology of Tourette Syndrome remain, several pharmacotherapies for tics have been studied, with varying results in terms of efficacy and the strength of evidence. Areas covered: This literature review encompasses pharmacotherapies for tics. The pharmacotherapies discussed in this review include: alpha agonists, antipsychotics, topiramate, botulinum toxin, and dopamine depleters. Expert opinion: Once the presence of tics is confirmed and psychoeducation and support are provided to patients and caregivers, one must examine the degree of tic-related impairment and the presence of psychiatric comorbidities. These factors influence treatment decisions as the presence of comorbidity and related impairment may shift the treatment target. When selecting a medication for tics, the presence of ADHD (the most frequent comorbidity) strengthens the case for choosing an alpha agonist. The case for antipsychotic medications is strongest when tic-related impairment is severe and/or the tics are refractory to more conservative measures. All medications require drug safety monitoring procedures and reevaluation over time.Funding Information
- not funded
This publication has 111 references indexed in Scilit:
- A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Aripiprazole in Children and Adolescents With Tourette’s DisorderBritish Journal of Psychology, 2013
- Catecholamine influences on prefrontal cortical function: Relevance to treatment of attention deficit/hyperactivity disorder and related disordersPharmacology Biochemistry and Behavior, 2011
- Clonidine Extended-Release Tablets as Add-on Therapy to Psychostimulants in Children and Adolescents With ADHDPEDIATRICS, 2011
- Efficacy and safety of topiramate on weight loss: a meta‐analysis of randomized controlled trialsObesity Reviews, 2011
- European clinical guidelines for Tourette syndrome and other tic disorders. Part II: pharmacological treatmentEuropean Child & Adolescent Psychiatry, 2011
- Definition and classification of hyperkinetic movements in childhoodMovement Disorders, 2010
- Tetrabenazine as anti-chorea therapy in Huntington Disease: an open-label continuation study. Huntington Study Group/TETRA-HD InvestigatorsBMC Neurology, 2009
- Short-term Sulpiride Treatment of Children and Adolescents With Tourette Syndrome or Chronic Tic DisorderJournal of the Formosan Medical Association, 2009
- Tic disorders and ADHD: answers from a world-wide clinical dataset on Tourette syndromeEuropean Child & Adolescent Psychiatry, 2007
- Management of Gilles de la Tourette Syndrome Using SulpirideClinical Neuropharmacology, 1990